Cite
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
MLA
Giovannetti, Elisa, et al. “Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells.” Molecular Pharmacology, vol. 73, no. 4, Apr. 2008, pp. 1290–300. EBSCOhost, https://doi.org/10.1124/mol.107.042382.
APA
Giovannetti, E., Lemos, C., Tekle, C., Smid, K., Nannizzi, S., Rodriguez, J. A., Ricciardi, S., Danesi, R., Giaccone, G., & Peters, G. J. (2008). Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Molecular Pharmacology, 73(4), 1290–1300. https://doi.org/10.1124/mol.107.042382
Chicago
Giovannetti, Elisa, Clara Lemos, Christina Tekle, Kees Smid, Sara Nannizzi, José A Rodriguez, Simona Ricciardi, Romano Danesi, Giuseppe Giaccone, and Godefridus J Peters. 2008. “Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells.” Molecular Pharmacology 73 (4): 1290–1300. doi:10.1124/mol.107.042382.